You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/131541
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPertega-Gomes, Nelma-
dc.contributor.authorVizcaino, José R.-
dc.contributor.authorFelisbino, Sérgio Luis-
dc.contributor.authorWarren, Anne Y.-
dc.contributor.authorShaw, Greg-
dc.contributor.authorKay, Jonathan-
dc.contributor.authorWhitaker, Hayley-
dc.contributor.authorLynch, Andy G.-
dc.contributor.authorFryer, Lee-
dc.contributor.authorNeal, David E.-
dc.contributor.authorMassie, Charles E.-
dc.date.accessioned2015-12-07T15:37:15Z-
dc.date.accessioned2016-10-25T21:23:47Z-
dc.date.available2015-12-07T15:37:15Z-
dc.date.available2016-10-25T21:23:47Z-
dc.date.issued2015-08-28-
dc.identifierhttp://dx.doi.org/10.18632/oncotarget.4328-
dc.identifier.citationOncotarget, v. 6, n. 25, p. 21675-21684, 2015.-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/11449/131541-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/131541-
dc.description.abstractMonocarboxylate Transporter 2 (MCT2) is a major pyruvate transporter encoded by the SLC16A7 gene. Recent studies pointed to a consistent overexpression of MCT2 in prostate cancer (PCa) suggesting MCT2 as a putative biomarker and molecular target. Despite the importance of this observation the mechanisms involved in MCT2 regulation are unknown. Through an integrative analysis we have discovered that selective demethylation of an internal SLC16A7/MCT2 promoter is a recurrent event in independent PCa cohorts. This demethylation is associated with expression of isoforms differing only in 5'-UTR translational control motifs, providing one contributing mechanism for MCT2 protein overexpression in PCa. Genes co-expressed with SLC16A7/MCT2 also clustered in oncogenic-related pathways and effectors of these signalling pathways were found to bind at the SLC16A7/MCT2 gene locus. Finally, MCT2 knock-down attenuated the growth of PCa cells. The present study unveils an unexpected epigenetic regulation of SLC16A7/MCT2 isoforms and identifies a link between SLC16A7/MCT2, Androgen Receptor (AR), ETS-related gene (ERG) and other oncogenic pathways in PCa. These results underscore the importance of combining data from epigenetic, transcriptomic and protein level changes to allow more comprehensive insights into the mechanisms underlying protein expression, that in our case provide additional weight to MCT2 as a candidate biomarker and molecular target in PCa.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
dc.format.extent21675-21684-
dc.language.isoeng-
dc.publisherOncotarget-
dc.sourcePubMed-
dc.subjectCastrate resistant diseaseen
dc.subjectMalignant phenotypeen
dc.subjectMonocarboxylate transporter 2en
dc.subjectProstate canceren
dc.titleEpigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate canceren
dc.typeoutro-
dc.contributor.institutionCRUK Cambridge Institute-
dc.contributor.institutionCentro Hospitalar do Porto-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionCambridge University Hospitals NHS Foundation Trust-
dc.contributor.institutionUniversity College London-
dc.description.affiliationUro-oncology Research Group, CRUK Cambridge Institute, Cambridge, UK-
dc.description.affiliationDepartment of Pathology, Centro Hospitalar do Porto, Porto, Portugal-
dc.description.affiliationDepartment of Morphology, Institute of Biosciences, Sao Paulo State University (UNESP), Sao Paulo, Brazil-
dc.description.affiliationDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK-
dc.description.affiliationMolecular Diagnostics and Therapeutics Group, University College London, London, UK-
dc.description.affiliationStatistics and Computational Biology Group, CRUK Cambridge Institute, Cambridge, UK-
dc.description.affiliationDepartment of Urology, University of Cambridge, Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK.-
dc.description.affiliationUnespDepartment of Morphology, Institute of Biosciences, São Paulo State University (UNESP), São Paulo, Brazil.-
dc.description.sponsorshipIdFAPESP: 2013/08830-2-
dc.description.sponsorshipIdFAPESP: 2013/06802-1-
dc.identifier.doi10.18632/oncotarget.4328-
dc.rights.accessRightsAcesso aberto-
dc.identifier.filePM26035357.pdf-
dc.relation.ispartofOncotarget-
dc.identifier.pubmed26035357-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.